Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

´ëÀå¾Ï HT29 ¼¼Æ÷ÁÖ¿Í Methotrexate ¾à¹°ÀúÇ× ¾Æ¼¼Æ÷ÁÖ¿¡¼­ÀÇ ¹Â½Å À¯ÀüÀÚÇ¥ÇöÀÇ º¯È­ Differential Mucin Gene Expression Associated with Methotrexate Resistance of Human Colonic Adenocarcinoma Cell Line, HT29

´ëÇѾÏÇÐȸÁö 1997³â 29±Ç 6È£ p.977 ~ 983
À̺ÀÈ­, È«Çü±â,
¼Ò¼Ó »ó¼¼Á¤º¸
À̺ÀÈ­ (  ) 
ÇѾç´ëÇб³ ÀÇ°ú´ëÇÐ °£È£Çаú

È«Çü±â (  ) 
UCSF ¼ÒÈ­±â¿¬±¸¼Ò

Abstract

¼­·Ð
¹Â½ÅÀÌ ¿©·¯ °¡Áö Á¾·ù°¡ ÀÖ´Ù´Â »ç½ÇÀº °ú°ÅºÎÅÍ ÀÎÁ¤µÇ°í ÀÖ¾úÀ¸¸ç ƯÈ÷ º´¸®Á¶Á÷ÇÐÀÚ
µé¿¡ ÀÇÇÏ¿© ¹Â½ÅÀ» ¿©·¯ °¡Áö ¹æ¹ýÀ¸·Î ¿°»öÇÔÀ¸·Î¼­ ¼¼Æ÷ÀÇ ±â´É°ú ¹Â½Å°úÀÇ °ü°è¸¦ ¹àÈ÷
·Á´Â ³ë·ÂÀÌ ÀÖ¾î¿Ô´Ù. ±×·¯³ª ¹Â½ÅÀÇ ºÐÀÚ·®ÀÌ Å©°í Á¤Á¦ ¹× Á¢±ÙÀÌ ¾î·Á¿ö ±× ±¸Á¶ ¹× ±â
´ÉÀÌ ¹àÇôÁöÁö ¾Ê¾ÒÀ¸³ª ÃÖ±Ù ¼¼Æ÷ ¹× ºÐÀÚ»ý¹°ÇÐÀÇ ¹ßÀüÀ¸·Î ¹Â½Å¿¡ ´ëÇÑ ½Åºñ°¡ ÇѲ¨Ç®¾¿
¹þ°ÜÁö°í ÀÖ´Ù. ¹Â½ÅÀº ¼ÒÈ­Àå°ü, È£Èí±â, ºñ´¢±â, »ý½Ä±â µî, ¿ì¸® ¸öÀÇ ´Ù¼öÀå±â¿¡¼­ ´Ù·®
À¸·Î ºÐºñµÇ¹Ç·Î ÀÌµé ±â°ü¿¡¼­ ¹ß»ýµÇ´Â ¾ÏÀÇ ¹ß»ý ¹× ¼ºÀå¿¡ ¸¹Àº ¿µÇâÀÌ ÀÖÀ¸¸®¶ó°í ±â
´ëµÈ´Ù. ¾Ï¼¼Æ÷¿¡¼­ ºÐºñµÇ´Â ¹Â½ÅÀº Á¤»ó¼¼Æ÷ÀÇ ¹Â½Å°ú´Â »óÀÌÇÑ °æ¿ì°¡ ¸¹´Ù. ¹Â½ÅÀº ºÐºñ
µÇ´Â Àå±â³ª ¼¼Æ÷¿¡ µû¶ó¼­ ƯÀ̼ºÀ» °®°í ÀÖÀ¸³ª ¾Ï¼¼Æ÷¿¡¼­´Â ÀÌ·¯ÇÑ Àå±â ƯÀ̼ºÀÌ ¼Ò½Ç
µÇ´ø°¡ ºñÁ¤»óÀÇ ¹Â½ÅÀÌ ºÐºñµÈ´Ù. ¾ÏÈ­ °úÁ¤¿¡ µû¶ó¼­ º¯È­µÈ ÇüÅÂÀÇ ¹Â½ÅÀÌ °üÂûµÇ¸ç Ư
È÷ ¸»ÃÊÇ÷¾×¿¡ ´Ù·®ÀÇ ¹Â½ÅÀÌ ¼øȯµÇ¹Ç·Î À̵éÀ» Ç×ü¸¦ ÀÌ¿ëÇÏ¿© °ËÃâÇÏ´Â °ÍÀÌ °¡´ÉÇÏ´Ù.
ÇöÀç±îÁö ¹àÇôÁø ¹Â½ÅÀº ¾ÆÆ÷¹Â½ÅÀÇ ±¸Á¶¿¡ µû¶ó¼­ MUC1¿¡¼­ºÎÅÍ MUC8 ±îÁö ºÐ·ùµÈ´Ù.
¾Ï¼¼Æ÷¿¡¼­ÀÇ ¼¼Æ÷°íÀ¯ÀÇ ¹Â½ÅÀÌ ¾Æ´Ñ ¹Â½ÅÀÌ ºÐºñµÇ´Â °æ¿ì´Â ¾ÏÈ­°úÁ¤¿¡ ¹ß»ýµÈ À¯ÀüÀÚ
¹ßÇöÀÌ ÀÌ»óÀ̶ó°í º¼ ¼ö ÀÖ´Ù. ±× ¿øÀÎÀÇ Ã¹Â°´Â ¹Â½ÅÀ¯ÀüÀÚÀÇ º¯È­µÈ ¹ßÇö(altered gene
expression)ÀÌ°í µÑ°´Â ¹Â½ÅÀ¯ÀüÀÚÀÇ ¼Ò½Ç µîÀÇ ºø³ª°£ ¹ßÇö (gene dysregulation) À̶ó°í
»ý°¢µÈ´Ù. ¿¹¸¦ µé¸é À§¿¡¼­ ¹ß°ßµÇ±â ¾î·Á¿î MUC2ÀÇ ºÐºñ°¡ À§¾Ï¼¼Æ÷¿¡¼­ ¹ß°ßµÇ´Â °æ¿ì
µîÀÌ´Ù. MUC2´Â ´ëÀå°ú ¼ÒÀåÀÇ ¹è ¼¼Æ÷¿¡¼­, MUC3´Â ¼ÒÀå°ú ´ëÀåÀÇ ¿ÞÁÖÇü Èí¼ö¼¼Æ÷¿¡
¼­, MUC5´Â À§ÀÇ Ç¥¸é»óÇǼ¼Æ÷¿¡¼­, MUC6´Â À§¼± ȤÀº À¯¹®¼±ÀÇ Á¡¾×°æ¼¼Æ÷¿¡¼­ Á¤»óÀû
À¸·Î ºÐºñµÇ´Â ¹Â½ÅÀÌ´Ù. ÀÌ·¯ÇÑ ¼¼Æ÷ ÈæÀº Àå±âƯÀ̼ºÀÌ ¼¼Æ÷ÀÇ ¹Ì¼¼È¯°æ
(microenvironment)À» º¯È­½ÃÅ´À¸·Î¼­ ¹Â½ÅÀ¯ÀüÀÚ ¹ßÇöÀÇ º¯È­¸¦ ÆľÇÇÏ´Â °ÍÀÌ ¹Â½ÅÀ¯ÀüÀÚ
¹ßÇö°úÁ¤À» ¹àÈ÷´Âµ¥¿¡ µµ¿òÀ» ÁÙ ¼ö ÀÖ´Ù. ¹Â½ÅÀ» ºÐºñÇÏ´Â ¸ðµç ¾ÏÀÇ Áø´Ü°ú Ä¡·á¿¡ ÀÌ¿ë
µÉ °¡´É¼ºµµ ÀÖ´Ù.
ÀúÀÚµéÀº ´ëÀå¾Ï ¼¼Æ÷ÁÖ¿¡¼­ ¾à¹°¿¡ ÀÇÇÏ¿© ȯ°æÀ» º¯È­½ÃÅ°°í, º¯È­¿¡ ÀûÀÀµÈ ¾Ï ¼¼Æ÷ÁÖ
¿¡¼­ ºÐºñµÇ´Â ¹Â½ÅÀ» °üÂûÇÔÀ¸·Î¼­ ¹Â½ÅÀ¯ÀüÀÚÀÇ º¯È­µÈ ¹Â½Å´Ü¹é¹ßÇöÀ» ±¸¸íÇÏ°íÀÚ ÇÏ¿´
´Ù.
#ÃÊ·Ï#
Purpose : In normal tissue, MUC2 mucin gene is expressed predominantly in goblet
cells, while MUC3 is expressed in both goblet cells and columnar absorptive cells of
small intestine and colon. MUC5 mucin genes are expressed predominantly in the
surface epithelial cells, while MUC6 is expressed mainly in the mucus neck cells of
gastric glands and pyloric glands of stomach. In this paper, we determined any changes
of mucin in drug-resistant cell lines from those parental cells, and we evaluated the
altered regulation of mucin production in drug-resistant cells.
Materials and Methods : In the study of 17 day postconfluent parental HT29 (HT29)
and methotrexate-resistant HT29 (HT29-MTX) colon cancer cell lines were examined
for the expression of MUC2, 3, 5 and 6 mucin polypeptide (apomucin) by Northern blot
and slot blot analysis, and also by immunoblot analysis.
Results : The level of MUC2 expression was unchanged, while there was increase in
MUC3 expression in HT29-MTX compared to HT29. Interestingly there was a marked
increase in the expression of MUC5 mRNA in HT29-MTX. The densitometric readings
expressed as HT29-MTX/HT29 at 17th day after the cells were confluent are MUC2
(1.1), MUC3 (1.3), MUC5 (>70), MUC6 (1.0) with RNA slot blot. Immunoblot analysis
was consistent with these data.
Conclusion : Marked induction in MUC5 but not MUC6 gastric mucin gene was found
in MTX resistance in HT29 colon cancer cells. The possible biological consequences of
altered regulation of mucin genes in drug resistant colon cancer cells require further
investigation.

Å°¿öµå

Mucin; HT29 cell; Drug resistance; Colon cancer; Gene expression;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KoreaMed
KAMS